Mereo BioPharma
About Mereo BioPharma
Mereo BioPharma is a London-headquartered biopharmaceutical company developing therapeutics for rare and specialty diseases.
Milestones
Milestones as listed on mereobiopharma.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.
Leadership Team
Leadership as listed on mereobiopharma.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.
Products & Services
Products and services as listed on mereobiopharma.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.
Setrusumab (UX-143)
Lead program in development for osteogenesis imperfecta, a rare genetic bone condition.
Source: mereobiopharma.comAlvelestat (MPH966)
Lead program for Alpha-1 Antitrypsin Deficiency-associated Lung Disease.
Source: mereobiopharma.comVantictumab (OMP-18R5)
For potential treatment of autosomal dominant osteopetrosis; partnered with āshibio.
Source: mereobiopharma.comLeflutrozole (BGS649)
For potential treatment of infertility in men with low testosterone; partnered with ReproNovo.
Source: mereobiopharma.comNavicixizumab (OMP305B83)
For potential treatment of post-platinum ovarian cancer; partnered with Feng Biosciences.
Source: mereobiopharma.comEtigilimab (MPH313)
For potential treatment of advanced or metastatic solid tumours; open to partnership.
Source: mereobiopharma.comAcumapimod (BCT197)
For potential treatment of acute exacerbations of COPD; open to partnership.
Source: mereobiopharma.comFinancials & Irish Entities
From the annual reports Mereo BioPharma Group plc files with the US Securities and Exchange Commission (10-K, US GAAP), in USD as reported. Latest financial year: to Dec 2025.
| Year to | Revenue | R&D | R&D % | Net income | Filing |
|---|---|---|---|---|---|
| Dec 2025 | $500,000 | $17.8m | >999% | −$41.9m | 10-K 2026 |
| Dec 2024 | $0 | $20.9m | — | −$43.3m | 10-K 2026 |
| Dec 2023 | $10.0m | $17.4m | 174.2% | −$29.5m | 10-K 2025 |
| Dec 2022 | $0 | $29.5m | — | −$42.2m | 10-K 2024 |
Each year is taken from the most recent annual report that includes it, so earlier years reflect any later restatement. Source: SEC EDGAR (XBRL financial data). Compare companies on the pharma company financials register.